AKNE-MYCIN
LOE ApproachingNDATOPICALOINTMENT
Approved
Jan 1985
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AKNE-MYCIN is a topical ointment approved in 1985 for acne treatment. The mechanism of action and specific active ingredient are not publicly detailed in available data. This is a legacy small-molecule dermatology product with a mature market presence.
LOE Approaching
Product is nearing loss of exclusivity with moderate competitive pressure (30/100), signaling potential downsizing of brand support and transition to generic/lifecycle management.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on AKNE-MYCIN offers limited career growth given the LOE-approaching lifecycle stage and zero linked job openings. This role is best suited for professionals managing portfolio transitions, generic-to-brand conversions, or seeking stable but non-growth assignments in established dermatology.
Brand ManagerProduct Manager
Worked on AKNE-MYCIN at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.